CFSAN Priorities: Industry & Consumer Groups Weigh In On NDIs And More
This article was originally published in The Tan Sheet
Executive Summary
FDA should accept safety findings from outside expert panels when reviewing new dietary ingredient notifications, CHPA says in Aug. 25 comments on CFSAN priorities
You may also be interested in...
Industry Roundup: No GRAS For PHOs, Pfizer Expands In China, MusclePharm Targets Over-40 Consumers
Partially hydrogenated oils lose GRAS; Pfizer expands consumer product output in China; MusclePharm adding direct sales; U.K. requires registration, logo for online sales; and more news in brief.
Industry Roundup: No GRAS For PHOs, Pfizer Expands In China, MusclePharm Targets Over-40 Consumers
Partially hydrogenated oils lose GRAS; Pfizer expands consumer product output in China; MusclePharm adding direct sales; U.K. requires registration, logo for online sales; and more news in brief.
Synthetics Stance In NDI Guidance Raises Red Flag For Industry
FDA's draft guidance on new dietary ingredient notifications already is arousing fierce pushback from the supplement industry over what constitutes an NDI and which substances cannot be dietary ingredients at all.